Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease, and pulmonary arterial hypertension linked to congenital heart disease—comparing them with matched control groups over a decade spanning 2008 to 2019.
The findings reveal escalating costs both before and after diagnosis. Even before patients received their official pulmonary arterial hypertension diagnosis, they were already incurring substantially higher societal costs than their healthy counterparts, ranging from nearly three to more than four times the expense. While productivity losses dominated the pre-diagnosis landscape, healthcare expenditures took center stage afterward, increasing by five to nearly eight times across the different pulmonary arterial hypertension categories.
The study highlights differences in cost patterns across subgroups that could inform more tailored approaches to disease management and resource allocation.
Citation
Kjellström B, Ivarsson B, Husberg M, Levin LÅ, Bernfort L. Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries. Pulm Circ. 2025 Apr 17;15(2):e70074. doi: 10.1002/pul2.70074. PMID: 40248212; PMCID: PMC12005055.
